🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

William Irvin

Bon Secours Health System

ORCID: 0009-0000-4033-9541
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
1.9Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 12 papers — median percentile 44. Top paper: “Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)”.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

New England Journal of Medicine(2025)10.1056/nejmoa2414859
N/A
1.2DataRank · unranked
93 citations

Hanna Bandos, Julia White, Thomas B. Julian, Atif J. Khan, Simona F. Shaitelman +23 more

Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer

Future Oncology(2021)10.2217/fon-2021-0753
N/A
0.901DataRank · unranked
30 citations

Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss +12 more

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf032
N/A
0.208DataRank · unranked
3 citations

Sungjin Kim, N. Lynn Henry, Ron D. Hays, Vinícius F. Calsavara, Michael Luu +11 more

A video intervention to improve patient understanding of tumor genomic testing in patients with cancer

Cancer Medicine(2024)10.1002/cam4.70095
N/A
0.104DataRank · unranked
1 citations

Lai Y. Wei, Amanda Ewart Toland, Carolyn J. Presley, Heather L. Hampel, Tasleem J. Padamsee +8 more

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12003
N/A
0DataRank · unranked
11 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +9 more

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer

medRxiv(2023)10.1101/2023.12.05.23299443
N/A
0DataRank · unranked
0 citations

Lai Wei, Amanda E. Toland, Carolyn J. Presley, Heather Hampel, Tasleem J. Padamsee +8 more

Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12024
N/A
0DataRank · unranked
0 citations

Joseph M. Unger, Dawn L. Hershman, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan +8 more

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

UNC Libraries(2020)10.17615/wwde-9r73
N/A
0DataRank · unranked
0 citations

Frances A. Collichio, Philip S. Bernard, Robert Z. Orlowski, Inge J. Stijleman, Anastasia Ivanova +5 more

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors

UNC Libraries(2020)10.17615/4edx-db25
N/A
0DataRank · unranked
0 citations

Bert H. O’Neil, William Irvin, Kimberly L. Keller, Larry W. Buie, Hanna K. Sanoff +6 more

A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.36_suppl.360922
N/A
0DataRank · unranked
16 citations

Karla V. Ballman, Eric P. Winer, Thomas H. Openshaw, Olwen Hahn, Frederick Briccetti +10 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623
Top 100%
0DataRank
Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more